Robust Immunity and Heterologous Protection against Influenza in Mice Elicited by a Novel Recombinant NP-M2e Fusion Protein Expressed in E. coli

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Wang, Wenling ^a   Huang, Baoying ^a   Jiang, Tao ^a   Wang, Xiuping ^a   Qi, Xiangrong ^a   Gao, Yingying ^a   Tan, Wenjie ^a   Ruan, Li ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGIC AGENT; MATRIX 2 NUCLEOPROTEIN FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; ESCHERICHIA COLI; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION RESISTANCE; INFLUENZA A; INFLUENZA VACCINATION; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN PURIFICATION;

ANIMALS; ANTIBODY FORMATION; ESCHERICHIA COLI; IMMUNITY; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION; IMMUNOGLOBULIN G; INFLUENZA A VIRUS; MICE; NUCLEOPROTEINS; ORTHOMYXOVIRIDAE INFECTIONS; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL MATRIX PROTEINS;

ESCHERICHIA COLI; MUS; ORTHOMYXOVIRIDAE;

EID: 84871361207     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052488     Document Type: Article

References (58)

1. Nichol KL, Treanor JJ, (2006) Vaccines for seasonal and pandemic influenza. J Infect Dis 194 S2N: S111-8.
2. Gerhard W, Mozdzanowska K, Zharikova D, (2006) Prospects for universal influenza virus vaccine. Emerg Infect Dis 12: 569-74.
3. Gerdil C, (2003) The annual production cycle for influenza vaccine. Vaccine 21: 1776-9.
4. Palese P, (2006) Making better influenza virus vaccines? Emerg Infect Dis 12: 61-5.
5. Fedson DS, (2005) Preparing for pandemic vaccination: an international policy agenda for vaccine development. J Public Health Policy 26: 4-29.
6. Livingston BD, Higgins D, Van Nest G, (2006) Evolving strategies for the prevention of influenza infection: potential for multistrain targeting. BioDrugs 20: 335-40.
7. Kaiser J, (2006) A one-size-fits-all flu vaccine? Science 312: 380-2.
8. Roy S, Kobinger GP, Lin J, Figueredo J, Calcedo R, et al. (2007) Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine 25: 6845-51.
9. Altstein AD, Gitelman AK, Smirnov YA, Piskareva LM, Zakharova LG, et al. (2006) Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Arch Virol 151: 921-31.
10. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, et al. (2007) Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 13: 426-35.
11. Eliasson DG, El Bakkouri K, Schön K, Ramne A, Festjens E, et al. (2008) CTA1-M2e-DD: A novel mucosal adjuvant targeted influenza vaccine. Vaccine 26: 1243-52.
12. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, et al. (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26: 201-14.
13. Wu F, Huang JH, Yuan XY, Huang WS, Chen YH, (2007) Characterization of immunity induced by M2e of influenza virus. Vaccine 25: 8868-73.
14. Ernst WA, Kim HJ, Tumpey TM, Jansen AD, Tai W, et al. (2006) Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 24: 5158-68.
15. Fan J, Liang X, Horton MS, Perry HC, Citron MP, et al. (2004) Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22: 2993-3003.
16. Zhou C, Zhou L, Chen YH, (2012) Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice. Vaccine 30: 3463-9.
17. De Filette M, Martens W, Roose K, Deroo T, Vervalle F, et al. (2008) An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 283: 11382-7.
18. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, et al. (2011) Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29: 5145-52.
19. Talbot HK, Rock MT, Johnson C, Tussey L, Kavita U, et al. (2010) Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLoS One 5: e14442.
20. Saha S, Yoshida S, Ohba K, Matsui K, Matsuda T, et al. (2006) A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus. Virology 354: 48-57.
21. Rimmelzwaan GF, Fouchier RA, Osterhaus AD, (2007) Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol 18: 529-36.
22. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, et al. (2005) Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23: 5404-10.
23. Zhirnov OP, Isaeva EI, Konakova TE, Thoidis G, Piskareva LM, et al. (2007) Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1. Influenza Other Respi Viruses 1: 71-9.
24. Davis AR, Nayak DP, Ueda M, Hiti AL, Dowbenkot D, et al. (1981) Expression of antigenic determinants of the hemagglutinin gene of a human influenza virus in E. coli. Proc Natl Acad Sci USA 78: 5376-80.
25. Lo CY, Wu Z, Misplon JA, Price GE, Pappas C, et al. (2008) Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: Cold-adapted vaccine versus DNA prime-adenovirus boost strategies [J]. Vaccine 26: 2062-72.
26. Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, et al. (2007) Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin 3: 157-64.
27. Zhou D, Wu TL, Lasaro MO, Latimer BP, Parzych EM, et al. (2010) A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. Mol Ther 18: 2182-9.
28. Soboleski MR, Gabbard JD, Price GE, Misplon JA, Lo CY, (2011) Cold-adapted influenza and recombinant adenovirus vaccines induce cross- protective immunity against pH1N1 challenge in mice. PLoS One 6: e21937.
29. Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, et al. (2009) Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 27(47): 6512-21.
30. Price GE, Soboleski MR, Lo CY, Misplon JA, Quirion MR, et al. (2010) Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One 5(10): e13162.
31. Lalor PA, Webby RJ, Morrow J, Rusalov D, Kaslow DC, et al. (2008) Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis 197: 1643-52.
32. Bolhassani A, Safaiyan S, Rafati S (2011) Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer 10(3).
33. Barouch DH, Nabel GJ, (2005) Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 16: 149-156.
34. Song L, Nakaar V, Kavita U, Price A, Huleatt J, et al. (2008) Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS ONE 3: e2257.
35. Biesova Z, Miller MA, Schneerson R, Shiloach J, Green KY, et al. (2009) Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus. Vaccine 27: 6234-8.
36. Lamere MW, Moquin A, Lee FE, Misra RS, Blair PJ, et al. (2011) Regulation of antinucleoprotein IgG by systemic vaccination and Its effect on influenza virus clearance. J Virol 85: 5027-35.
37. Shim B-S, Choi YK, Yun C-H, Lee E-G, Jeon YS, et al. (2011) Sublingual Immunization with M2-Based Vaccine Induces Broad Protective Immunity against Influenza. PLoS ONE 6(11): e27953.
38. Reed SG, Bertholet S, Coler RN, Friede M, (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30: 23-32.
39. Treanor J, Nolan C, O'Brien D, Burt D, Lowell G, et al. (2006) Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 24: 254-62.
40. Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, et al. (2006) Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 80: 4962-70.
41. Mizuno D, Ide-Kurihara M, Ichinomiya T, Kubo I, Kido H, (2006) Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen. J Immunol 176: 1122-30.
42. Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, et al. (2006) A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Vaccine 24: 3990-4006.
43. De Filette M, Ramne A, Birkett A, Lycke N, Lowenadler B, et al. (2006) The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24: 544-51.
44. Huang BY, Wang WL, Wang XP, Jiang T, Tan WJ, et al. (2011) Efficient soluble expression and purification of influenza A nucleoprotein in Escherichia coli. Bing Du Xue Bao 27(1): 50-7.
45. Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, et al. (2008) Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 26: 3395-403.
46. Jegerlehner A, Schmitz N, Storni T, Bachmann MF, (2004) Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 172: 5598-605.
47. Denkers EY, Badger CC, Ledbetter JA, Bernstein ID, (1985) Influence of antibody isotype on passive serotherapy of lymphoma. J Immunol 135: 2183-6.
48. Stanekova Z, Vareckova E, (2010) Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J 7: 351.
49. Stanekova Z, Vareckova E, (2010) Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J 7: 351.
50. Tamura S, Kurata T, (2004) Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis 57: 236-47.
51. Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier RA, Osterhaus AD, et al. (2008) Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 82: 5161-6.
52. Lamere MW, Lam HT, Moquin A, Haynes L, Lund FE, et al. (2011) Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol 186: 4331-9.
53. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD, (2008) A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 181: 4168-76.
54. Marrack P, McKee AS, Munks MW, (2009) Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9: 287-93.
55. Bevan MJ, (2004) Helping the CD8(+) T-cell response. Nat Rev Immunol 4: 595-602.
56. Takeda K, Kaisho T, Akira S, (2003) Toll-like receptors. Annu Rev Immunol 21: 335-76.
57. Iwasaki A, Medzhitov R, (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5: 987-95.
58. McCluskie MJ, Weeratna RD, Clements JD, Davis HL, (2001) Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants. Vaccine 19: 3759-68.